Page last updated: 2024-10-31

midazolam and Panic Disorder

midazolam has been researched along with Panic Disorder in 5 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.

Research Excerpts

ExcerptRelevanceReference
" low-dose intranasal midazolam in five patients diagnosed with DSM-III-R panic disorder."9.07The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. ( Clary, C; Dever, AI; Mandos, LA; Schweizer, E, 1992)
" low-dose intranasal midazolam in five patients diagnosed with DSM-III-R panic disorder."5.07The use of low-dose intranasal midazolam to treat panic disorder: a pilot study. ( Clary, C; Dever, AI; Mandos, LA; Schweizer, E, 1992)
" Combined, chronic administration of these doses yielded a sustained synergism in motor performance impairment, which contrasted with the antagonism usually found between the benzodiazepines and methylxanthines when performance is evaluated by psychomotor tests not requiring fine motor control."1.28Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam. ( Falk, JL; Lau, CE, 1991)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Strauss, CV1
Vicente, MA1
Zangrossi, H3
de Paula Soares, V1
Bueno, CH1
Nogueira, RL1
Soares, VP1
Viana, MB1
Lau, CE1
Falk, JL1
Schweizer, E1
Clary, C1
Dever, AI1
Mandos, LA1

Trials

1 trial available for midazolam and Panic Disorder

ArticleYear
The use of low-dose intranasal midazolam to treat panic disorder: a pilot study.
    The Journal of clinical psychiatry, 1992, Volume: 53, Issue:1

    Topics: Administration, Intranasal; Adult; Double-Blind Method; Female; Humans; Male; Midazolam; Panic Disor

1992

Other Studies

4 other studies available for midazolam and Panic Disorder

ArticleYear
Activation of 5-HT1A receptors in the rat basolateral amygdala induces both anxiolytic and antipanic-like effects.
    Behavioural brain research, 2013, Jun-01, Volume: 246

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Dark Adapta

2013
Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats.
    Behavioural brain research, 2009, Jan-30, Volume: 197, Issue:1

    Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety Disorders; Avoidance Learning; Escape Re

2009
Panicolytic-like effect induced by the stimulation of GABAA and GABAB receptors in the dorsal periaqueductal grey of rats.
    European journal of pharmacology, 2005, Jun-15, Volume: 516, Issue:3

    Topics: Analysis of Variance; Animals; Anxiety Disorders; Avoidance Learning; Baclofen; Behavior, Animal; Ca

2005
Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam.
    Pharmacology, biochemistry, and behavior, 1991, Volume: 40, Issue:4

    Topics: Animals; Caffeine; Discrimination Learning; Drug Synergism; Male; Midazolam; Panic Disorder; Psychom

1991